Princeton’s WCG provides clinical research regulatory and ethical review services for human research, while Pennsylvania-based Vigilare International provides integrated, end-to-end pharmacovigilance and drug safety solutions for the biopharmaceutical and biotech industry.
“We are delighted to welcome Vigilare to the WCG family of companies,” said WCG Chairman and CEO Donald A. Deieso. “With its comprehensive service suite, Vigilare provides clients with streamlined, regulatory compliant operations, faster access to safety data and focused, in-depth product safety reporting and analysis. Vigilare saves clients time and money by offering them a robust alternative to building and maintaining an internal pharmacovigilance and drug safety program.”
Vigilare will continue to operate as an independent service organization.
“WCG is a perfect fit for Vigilare,” said Vigilare CEO and President James A. Bannon. “Our pharmacovigilance services are a natural complement to WCG’s existing portfolio of clinical research optimization solutions. We look forward to working with our colleagues at WCG to identify additional opportunities to streamline clinical research operations, while improving the quality of product safety information.”